Angiogenesis Inhibitor TNP-470 Reduces Human Pancreatic Cancer Growth

Journal of Gastrointestinal Surgery

Volumn 5, Issue 2, 2001, Pages 131-138

  Hotz, Hubert G ^a   Reber, Howard A ^a   Hotz, Birgit ^a   Sangbavi, Premal C ^a   Yu, Tina ^a   Foitzik, Thomas ^b   Buhr, Heinz J ^b   Hines, Oscar J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Angiogenesis; Endothelial cell; Pancreatic cancer; TNP 470; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLOHEXANE DERIVATIVE; ENDOTHELIAL CELL GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; LYMPHOKINE; O-(CHLOROACETYLCARBAMOYL)FUMAGILLOL; SESQUITERPENE; VASCULOTROPIN; VASCULOTROPIN A;

ADENOCARCINOMA; ANGIOGENESIS; ANIMAL; ARTICLE; CELL CULTURE; CELL DIVISION; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; EVALUATION; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NUDE MOUSE; PANCREAS TUMOR; RANDOMIZATION; SECRETION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; CELL DIVISION; CYCLOHEXANES; DISEASE MODELS, ANIMAL; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; IMMUNOHISTOCHEMISTRY; LYMPHOKINES; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PHYSIOLOGIC; PANCREATIC NEOPLASMS; RANDOM ALLOCATION; SESQUITERPENES; TUMOR CELLS, CULTURED; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035293380     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(01)80024-X     Document Type: Article

References (23)

1. Parker SL, Long T, Bolen S, Wingo PA. Cancer statistics. Ca Cancer J Clin 1997;47:5-27.
2. Yeo CJ, Cameron JL. Pancreatic cancer. Cur Probl Surg 1999;36:59-152.
3. Glimelius B. Chemotherapy in the treatment of cancer of the pancreas. J Hepatobiliary Pancreat Surg 1999;5:235-241.
4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
5. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844.
6. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J, Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990;6;348: 555-557.
7. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
8. Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol 1996;1:167-190.
9. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;4;339:58-61.
10. Ikeda N. Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H, Miyake M. Prognostic significance of angiogenesis in human pancreatic cancer. BrJ Cancer 1999;79:1553-1563.
11. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000;15;88:2239-2245.
12. Pluda JM, Parkinson DR. Clinical implications of rumor-associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas. Cancer 1996;1;78(3 Suppl):680-687.
13. Sunamura M, Sun L, Lozonschi L, Duda DG, Kodama T, Matsumoto G, Shimamura H, Takeda K, Kobari M, Hamada H, Matsuno S. The antiangiogenesis effect of interleukin 12 during early growth of human pancreatic cancer in SCID mice. Pancreas 2000;20:227-233.
14. Hotz HG, Hines OJ, Massod R, Hotz B, Gill PS, Reber HA. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Gastroenterology 2000;118:A176.
15. Castronovo V, Belotti D. TNP-470 (AGM-1470): Mechanisms of action and early clinical development. Eur J Cancer 1996;32A:2520-2527.
16. Hori A, Ikeyama S, Sudo K. Suppression of cyclin D1 mRNA expression by the angiogenesis inhibitor TNP-470 (AGM-1470) in vascular endothelial cells. Biochem Biophys Res Commun 1994;204:1067-1073.
17. Budson AE, Ko L, Brasel C, Bischoff J. The angiogenesis inhibitor AGM-1470 selectively increases E-selectin. Biochem Biophys Res Commun 1996;225:141-145.
18. Emoto M, Ishiguro M, Iwasaki H, Kikuchi M, Kawarabayashi T. TNP-470 inhibits growth and the production of vascular endothelial growth factor of uterine carcinosarcoma cells in vitro. Anticancer Res 2000;20:601-604.
19. Kumeda SI, Deguchi A, Toi M, Omura S, Umezawa K. Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells. Anticancer Res 1999;19:3961-3968.
20. Kawarada Y, Ishikura H, Kishimoto T, Saito K, Takahashi T, Kato H, Yoshiki T. Inhibitory effects of the antiangiogenic agent TNP-470 on establishment and growth of hematogenous metastasis of human pancreatic carcinoma in SCID beige mice in vivo. Pancreas 1997;15:251-257.
21. Shishido T, Yasoshima T, Denno R, Mukaiya M, Sato N, Hirata K. Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin. Jpn J Cancer Res 1998;89:963-969.
22. Bhargava P, Marshall JL, Rizvi N, Dahut W, Yoe J, Figuera M, Phipps K, Ong VS, Kato A, Hawkins MJ. A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 1999;5;1989-1995.
23. Mavligit G, Killian A, Tang RA, Gutterman JU, Kavanagh JJ. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 1997;3:1501-1505.